Sio Gene Therapies, Inc

(NASDAQ:AXGT)

Latest On Sio Gene Therapies, Inc (AXGT):

Date/Time Type Description Signal Details
2021-02-10 07:11 ESTFinancialsCompany financials have been released.Neutral
2021-01-02 15:11 ESTFinancialsCompany financials have been released.Neutral
2020-12-13 03:17 ESTFinancialsCompany financials have been released.Neutral
2020-11-20 11:13 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 03:13 ESTFinancialsCompany financials have been released.Neutral
2020-11-15 11:21 ESTFinancialsCompany financials have been released.Neutral
2020-11-11 13:17 ESTNewsAxovant Gene Therapies to become Sio Gene Therapies November 13N/A
2020-11-10 07:21 ESTNewsAxovant on go with pivotal study of gene therapy for rare inherited lipid disordersN/A
2020-11-04 11:11 ESTAnalyst RatingThe Analyst Target Price has decreased from $10.92 to $8.5.Neutral
2020-11-03 11:11 ESTAnalyst RatingThe Analyst Target Price has decreased from $12.5 to $10.92.Neutral
2020-11-02 16:37 ESTAnalyst RatingThe Analyst Target Price has decreased from $13.21 to $12.5.Neutral
2020-11-01 17:12 ESTFinancialsCompany financials have been released.Neutral
2020-10-30 11:20 ESTNewsAxovant sees delayed enrollment in Parkinson’s study with gene therapyN/A
2020-10-14 07:07 ESTNewsAxovant nabs Rare Pediatric Disease tag for AXO-AAV-GM2 in rare neurodegenerative disorderN/A
2020-10-09 22:57 ESTNewsAxovant Gene Therapies candidate nabs Rare Pediatric Disease tag for nerve cell disorderN/A
2020-10-08 17:28 ESTNewsNew commercial chief at Axovant Gene TherapiesN/A
2020-10-07 11:43 ESTNewsAxovant under pressure after selectively reporting gene therapy data in Parkinson'sN/A
2020-09-28 18:55 ESTNewsAxovant Offers An Interesting Risk-Reward PropositionN/A
2020-09-26 04:24 ESTFinancialsCompany financials have been released.Neutral
2020-09-16 13:37 ESTNewsAxovant partners with Viralgen for gene therapy development and manufacturingN/A
2020-08-18 08:11 ESTAnalyst RatingThe Analyst Target Price has decreased from $13.57 to $13.21.Neutral
2020-08-13 04:12 ESTFinancialsCompany financials have been released.Neutral
2020-08-12 12:12 ESTEarnings EstimateAn EPS average of -$0.48 is estimated for the quarter ending on December 31, 2020.Sell
2020-08-11 08:24 ESTNewsAxovant Gene Therapies EPS beats by $0.25N/A
2020-07-31 18:03 ESTNewsAxovant signs gene therapy supply deal with Oxford BiomedicaN/A
2020-07-31 00:16 ESTFinancialsCompany financials have been released.Neutral
2020-07-28 12:13 ESTFinancialsCompany financials have been released.Neutral
2020-07-23 16:20 ESTFinancialsCompany financials have been released.Neutral
2020-07-15 18:09 ESTInsider TradePavan Cheruvu has directly acquired 37,500 shares and currently holds 57,836 shares.Buy
2020-07-15 18:09 ESTInsider TradeAtul Pande has acquired 10,000 shares indirectly via Atul C. Pande & Patricia A Pande TR DTD 08/24/2017.Buy
2020-06-15 19:47 ESTInsider TradeGavin Corcoran has directly acquired 16,002 shares and currently holds 16,002 shares.Buy
2020-06-15 19:46 ESTInsider TradePavan Cheruvu has directly acquired 22,591 shares and currently holds 30,091 shares.Buy
2020-06-15 19:46 ESTInsider TradeDavid W. Nassif has directly acquired 15,060 shares and currently holds 24,210 shares.Buy
2020-06-13 00:12 ESTFinancialsCompany financials have been released.Neutral
2020-06-12 12:10 ESTAnalyst RatingThe Analyst Target Price has decreased from $19.29 to $13.57.Neutral
2020-06-11 08:11 ESTEarnings EstimateAn EPS average of -$2.19 is estimated for the 2022 year.Sell
2020-06-11 08:11 ESTEarnings EstimateAn EPS average of -$0.62 is estimated for the quarter ending on September 30, 2020.Sell
2020-06-11 08:11 ESTAnalyst RatingThe Analyst Target Price has decreased from $19.36 to $19.29.Neutral
2020-06-01 19:41 ESTNewsAssessing Axovant Gene TherapiesN/A
2020-05-31 16:38 ESTFinancialsCompany financials have been released.Neutral
2020-05-03 08:14 ESTFinancialsCompany financials have been released.Neutral
2020-04-20 08:10 ESTAnalyst RatingThe Analyst Target Price has decreased from $20.75 to $19.36.Neutral
2020-04-17 07:53 ESTNewsAxovant teams up with Invitae to identify gene therapy candidatesN/A
2020-04-17 07:44 ESTNewsBenchmark likes Regeneron in premarket analyst actionN/A
2020-04-11 03:50 ESTNewsAxovant Gene Therapies EPS beats by $0.01N/A
2020-04-11 03:43 ESTNewsAxovant Gene Therapies down 11% after hours on equity offeringN/A
2020-04-11 03:42 ESTNewsAxovant Gene Therapies prices stock offering at $3.75N/A
2020-04-11 03:12 ESTNewsSelloff creating bargains in healthcare - BairdN/A
2020-04-10 20:10 ESTAnalyst RatingThe Analyst Target Price has decreased from $21 to $20.75.Neutral
2020-04-07 12:11 ESTFinancialsCompany financials have been released.Neutral

About Sio Gene Therapies, Inc (AXGT):

Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing various product candidates for debilitating neurodegenerative diseases. The company's clinical-stage programs include AXO-Lenti-PD program for the treatment of Parkinson's disease; AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis. It has a license agreement with Oxford BioMedica (UK) Ltd. and The University of Massachusetts Medical School. The company was formerly known as Axovant Sciences Ltd. and changed its name to Axovant Gene Therapies Ltd. in March 2019. Axovant Gene Therapies Ltd. was founded in 2014 and is based in London, the United Kingdom.

AXGT Quotes by TradingView

See Advanced Chart

General

  • Name Sio Gene Therapies, Inc
  • Symbol AXGT
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 38
  • Last Split Factor1:8
  • Last Split Date2019-05-08
  • Fiscal Year EndMarch
  • IPO Date2015-06-11
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Web URLhttp://www.axovant.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 1.73
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Current Year EPS Estimate -$1.11
  • Next Year EPS Estimate -$1.28
  • Next Quarter EPS Estimate -$0.32
  • Return on Assets -37%
  • Earnings Per Share -$5.71
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 99.22 million
  • EBITDA -103562000
  • Analyst Target Price $8.5
  • Book Value Per Share $1.43
View More

Share Statistics

  • Shares Outstanding 47.25 million
  • Shares Float 19.57 million
  • % Held by Insiders 3957%
  • % Held by Institutions 24.27%
  • Shares Short 1.44 million
  • Shares Short Prior Month 526502
  • Short Ratio 0.65
  • Short % of Float 7%
  • Short % of Shares Outstanding 4%
View More

Technicals

  • Beta 1.58
  • 52 Week High $5.74
  • 52 Week Low $1.76
  • 50 Day Moving Average 2.84
  • 200 Day Moving Average 3.1
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
View More

Sio Gene Therapies, Inc (AXGT) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Sio Gene Therapies, Inc (AXGT) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-13$N/A-$0.21-$0.2927.59%
2020-06-302020-08-11$N/A-$0.20-$0.4454.55%
2020-03-312020-06-10$N/A-$0.54-$0.586.9%
2019-12-312020-02-10$N/A-$0.62-$0.677.46%
2019-09-302019-11-08$N/A-$0.61-$1.0944.04%
2019-06-302019-08-09$N/A-$1.23-$0.91-35.16%
2019-03-312019-06-11$N/A-$0.45-$1.7073.53%
2018-12-312019-02-07$N/A-$2.16-$2.08-3.85%
2018-09-302018-11-07$N/A-$2.24-$2.9223.29%
2018-06-302018-08-07$N/A-$3.84-$1.47-161.22%
2018-03-312018-06-11$N/A-$1.84-$2.9136.77%
2017-12-312018-02-09$N/A-$4.32-$3.97-8.82%
2017-09-302017-11-02$N/A-$5.12-$4.41-16.1%
2017-06-302017-08-07$N/A-$5.20-$4.25-22.35%
2017-03-312017-06-13$N/A-$4.24-$4.11-3.16%
2016-12-312017-02-14$N/A-$0.48-$0.46-4.35%
2016-09-302016-11-07$N/A-$0.43-$0.37-16.22%
2016-06-302016-08-15$N/A-$0.38-$0.36-5.56%
2016-03-312016-06-06$N/A-$0.30-$0.28-7.14%
2015-12-312016-02-09$N/A-$0.64-$0.15-326.67%
2015-09-302015-11-02$N/A-$0.12-$0.2347.83%
2015-06-302015-08-11$N/A-$0.35-$0.11-218.18%

Sio Gene Therapies, Inc (AXGT) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development 6.41 million 5.06 million N/A 10.92 million 8.27 million
Income Before Tax -10.7 million -10.13 million N/A -16.37 million -14.05 million
Selling General Administrative 4.3 million 4.49 million N/A 5.13 million 5.41 million
Gross Profit -1000 N/A N/A N/A N/A
Ebit -10.7 million -9.51 million N/A -15.21 million -13.68 million
Operating Income -10.7 million -9.55 million N/A -16.05 million -13.68 million
Income Tax Expense -188000 N/A 30000 282000 -9000
Total Revenue N/A N/A N/A N/A N/A
Cost of Revenue 1000 N/A N/A N/A N/A
Total Other Income Expense Net N/A -580000 N/A 127000 -372000
Net Income From Continuing Operations -10.52 million -9.98 million N/A -16.65 million -14.04 million
Net Income Applicable to Common Shares -10.52 million N/A -8.59 million -16.65 million -14.04 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments -111000 N/A -5000 N/A N/A
Change to Liabilities N/A -1.44 million 4.06 million -1.22 million -1.33 million
Total Cash Flow from Investing Activities N/A -19000 -5000 -76000 -96000
Net Borrowings N/A -15.73 million N/A -19.31 million -5.21 million
Total Cash Flow from Financial Activities 19.62 million N/A 70.86 million -19.28 million -5.08 million
Change to Operating Activities N/A -3.4 million -8.36 million -211000 -4.8 million
Change in Cash 7.69 million N/A 52.94 million -32.44 million -23.92 million
Total Cash from Operating Activities -11.82 million -13.5 million -17.91 million -13.09 million -18.75 million
Depreciation 622000 N/A 716000 849000 734000
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities N/A N/A N/A N/A N/A
Change to Net Income N/A -979000 2.04 million 1.45 million 684000
Capital Expenditures 111000 N/A 5000 76000 96000
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities 9.94 million 10.1 million N/A 32.12 million 37.22 million
Total Stockholder Equity 89.03 million 69.67 million N/A 61.56 million 5.05 million
Other Current Liabilities 240000 N/A N/A N/A N/A
Total Assets 98.96 million 79.77 million N/A 93.68 million 42.26 million
Common Stock 1000 N/A N/A N/A N/A
Other Current Assets 6.27 million N/A N/A N/A 1.8 million
Retained Earnings -787.74 million -777.22 million -767.24 million -758.64 million -742 million
Other Liabilities N/A N/A N/A N/A N/A
Other Assets N/A N/A 46000 46000 46000
Cash 81.02 million 63.17 million N/A 80.75 million 27.81 million
Total Current Liabilities 8.95 million 10.04 million N/A 32.04 million 30.69 million
Other Stockholder Equity 343000 N/A -11000 -55000 198000
Property, Plant & Equipment 463000 N/A 1.74 million 2.33 million 2.93 million
Total Current Assets 97.03 million 70.32 million N/A 85.43 million 33.42 million
Long Term Investments N/A 8.06 million N/A 5.87 million 5.87 million
Net Tangible Assets 89.03 million N/A 58.58 million 61.56 million 5.05 million
Short Term Investments 8.06 million N/A N/A N/A N/A
Long Term Debt N/A N/A N/A N/A 6.45 million
Inventory N/A N/A N/A N/A N/A
Accounts Payable 8.71 million 2.17 million N/A 4.41 million 347000

Sio Gene Therapies, Inc (AXGT) Chart:

Sio Gene Therapies, Inc (AXGT) News:

Below you will find a list of latest news for Sio Gene Therapies, Inc (AXGT) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Sio Gene Therapies, Inc (AXGT) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Sio Gene Therapies, Inc (AXGT) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-15EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1636050/999999999520001423/9999999995-20-001423-index.htm
2020-01-16UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1636050/000000000020000411/0000000000-20-000411-index.htm
2019-03-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000089924319008356/0000899243-19-008356-index.htm
2019-07-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000089924319019546/0000899243-19-019546-index.htm
2018-12-20SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1636050/000090342318000642/0000903423-18-000642-index.htm
2019-01-03SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1636050/000090342319000002/0000903423-19-000002-index.htm
2019-01-103Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000090342319000014/0000903423-19-000014-index.htm
2019-03-19SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1636050/000090342319000150/0000903423-19-000150-index.htm
2019-03-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000090342319000151/0000903423-19-000151-index.htm
2019-03-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000090342319000152/0000903423-19-000152-index.htm
2019-07-12SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1636050/000090342319000287/0000903423-19-000287-index.htm
2019-07-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000090342319000296/0000903423-19-000296-index.htm
2019-07-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000090342319000297/0000903423-19-000297-index.htm
2019-03-13424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1636050/000104746919001193/0001047469-19-001193-index.htm
2019-03-15424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1636050/000104746919001268/0001047469-19-001268-index.htm
2020-01-10S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1636050/000104746920000182/0001047469-20-000182-index.htm
2020-02-19PRE 14COther preliminary information statementshttps://www.sec.gov/Archives/edgar/data/1636050/000104746920000930/0001047469-20-000930-index.htm
2020-02-19424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1636050/000104746920000944/0001047469-20-000944-index.htm
2020-02-21424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1636050/000104746920000971/0001047469-20-000971-index.htm
2020-03-02DEF 14COther definitive information statementshttps://www.sec.gov/Archives/edgar/data/1636050/000104746920001128/0001047469-20-001128-index.htm
2020-04-29424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1636050/000104746920002712/0001047469-20-002712-index.htm
2020-06-11S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1636050/000104746920003544/0001047469-20-003544-index.htm
2020-10-02424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1636050/000104746920005081/0001047469-20-005081-index.htm
2019-03-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636050/000110465919014921/0001104659-19-014921-index.htm
2019-03-19SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1636050/000110465919016007/0001104659-19-016007-index.htm
2019-03-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000110465919016010/0001104659-19-016010-index.htm
2019-03-19SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1636050/000110465919016025/0001104659-19-016025-index.htm
2019-03-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000110465919016034/0001104659-19-016034-index.htm
2019-03-19SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1636050/000110465919016037/0001104659-19-016037-index.htm
2019-03-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000110465919016043/0001104659-19-016043-index.htm
2019-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000110465919040419/0001104659-19-040419-index.htm
2019-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000110465919040423/0001104659-19-040423-index.htm
2019-07-16SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1636050/000110465919040590/0001104659-19-040590-index.htm
2019-07-16SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1636050/000110465919040592/0001104659-19-040592-index.htm
2019-07-17SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1636050/000110465919040601/0001104659-19-040601-index.htm
2019-09-06SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1636050/000110465919049115/0001104659-19-049115-index.htm
2019-12-31SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1636050/000110465919077344/0001104659-19-077344-index.htm
2020-02-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636050/000110465920022534/0001104659-20-022534-index.htm
2020-02-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636050/000110465920023963/0001104659-20-023963-index.htm
2020-02-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000110465920026412/0001104659-20-026412-index.htm
2020-02-28SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1636050/000110465920026472/0001104659-20-026472-index.htm
2020-03-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636050/000110465920038805/0001104659-20-038805-index.htm
2020-04-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636050/000110465920053503/0001104659-20-053503-index.htm
2020-06-11CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1636050/000110465920072458/0001104659-20-072458-index.htm
2020-10-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636050/000110465920111774/0001104659-20-111774-index.htm
2020-10-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636050/000110465920112406/0001104659-20-112406-index.htm
2020-10-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636050/000110465920113239/0001104659-20-113239-index.htm
2019-03-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000114420419014887/0001144204-19-014887-index.htm
2019-03-19SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1636050/000114420419014888/0001144204-19-014888-index.htm
2019-07-12SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1636050/000114420419034588/0001144204-19-034588-index.htm
2019-07-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000114420419034597/0001144204-19-034597-index.htm
2020-02-11SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1636050/000117891320000347/0001178913-20-000347-index.htm
2020-02-25SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1636050/000117891320000643/0001178913-20-000643-index.htm
2019-03-19SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1636050/000119312519079656/0001193125-19-079656-index.htm
2019-03-19SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1636050/000119312519079684/0001193125-19-079684-index.htm
2019-07-12SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1636050/000119312519193234/0001193125-19-193234-index.htm
2019-07-12SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1636050/000119312519193291/0001193125-19-193291-index.htm
2019-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1636050/000119380519000190/0001193805-19-000190-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1636050/000119380520000198/0001193805-20-000198-index.htm
2019-03-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000120919119020327/0001209191-19-020327-index.htm
2019-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000120919119025187/0001209191-19-025187-index.htm
2019-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000120919119025188/0001209191-19-025188-index.htm
2019-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000120919119025189/0001209191-19-025189-index.htm
2019-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000120919119025190/0001209191-19-025190-index.htm
2019-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000120919119025191/0001209191-19-025191-index.htm
2019-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000120919119025192/0001209191-19-025192-index.htm
2019-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000120919119025194/0001209191-19-025194-index.htm
2019-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000120919119025195/0001209191-19-025195-index.htm
2019-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000120919119025197/0001209191-19-025197-index.htm
2019-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000120919119037522/0001209191-19-037522-index.htm
2019-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000120919119037525/0001209191-19-037525-index.htm
2019-07-013Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000120919119039814/0001209191-19-039814-index.htm
2019-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000120919119039818/0001209191-19-039818-index.htm
2019-07-023Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000120919119040473/0001209191-19-040473-index.htm
2019-07-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000120919119040520/0001209191-19-040520-index.htm
2019-07-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000120919119041997/0001209191-19-041997-index.htm
2020-02-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000120919120010732/0001209191-20-010732-index.htm
2020-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000120919120020125/0001209191-20-020125-index.htm
2020-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000120919120025015/0001209191-20-025015-index.htm
2020-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000120919120025016/0001209191-20-025016-index.htm
2020-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000120919120025017/0001209191-20-025017-index.htm
2020-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000120919120025018/0001209191-20-025018-index.htm
2020-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000120919120025020/0001209191-20-025020-index.htm
2020-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000120919120025022/0001209191-20-025022-index.htm
2020-04-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000120919120025023/0001209191-20-025023-index.htm
2020-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000120919120036804/0001209191-20-036804-index.htm
2020-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000120919120036807/0001209191-20-036807-index.htm
2020-06-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000120919120036808/0001209191-20-036808-index.htm
2020-07-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000120919120042215/0001209191-20-042215-index.htm
2020-07-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000120919120042216/0001209191-20-042216-index.htm
2020-10-073Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000120919120054254/0001209191-20-054254-index.htm
2020-10-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000120919120054255/0001209191-20-054255-index.htm
2019-02-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636050/000163605019000010/0001636050-19-000010-index.htm
2019-02-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1636050/000163605019000012/0001636050-19-000012-index.htm
2019-02-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636050/000163605019000021/0001636050-19-000021-index.htm
2019-02-21PRE 14COther preliminary information statementshttps://www.sec.gov/Archives/edgar/data/1636050/000163605019000023/0001636050-19-000023-index.htm
2019-03-04DEF 14COther definitive information statementshttps://www.sec.gov/Archives/edgar/data/1636050/000163605019000025/0001636050-19-000025-index.htm
2019-03-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636050/000163605019000028/0001636050-19-000028-index.htm
2019-04-05PRE 14COther preliminary information statementshttps://www.sec.gov/Archives/edgar/data/1636050/000163605019000030/0001636050-19-000030-index.htm
2019-04-15DEF 14COther definitive information statementshttps://www.sec.gov/Archives/edgar/data/1636050/000163605019000036/0001636050-19-000036-index.htm
2019-04-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636050/000163605019000040/0001636050-19-000040-index.htm
2019-06-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636050/000163605019000043/0001636050-19-000043-index.htm
2019-06-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636050/000163605019000049/0001636050-19-000049-index.htm
2019-06-1110-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1636050/000163605019000053/0001636050-19-000053-index.htm
2019-07-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636050/000163605019000056/0001636050-19-000056-index.htm
2019-07-16DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1636050/000163605019000062/0001636050-19-000062-index.htm
2019-07-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636050/000163605019000065/0001636050-19-000065-index.htm
2019-08-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1636050/000163605019000069/0001636050-19-000069-index.htm
2019-08-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636050/000163605019000070/0001636050-19-000070-index.htm
2019-08-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636050/000163605019000073/0001636050-19-000073-index.htm
2019-09-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636050/000163605019000075/0001636050-19-000075-index.htm
2019-09-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636050/000163605019000083/0001636050-19-000083-index.htm
2019-09-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000163605019000084/0001636050-19-000084-index.htm
2019-09-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000163605019000085/0001636050-19-000085-index.htm
2019-09-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1636050/000163605019000086/0001636050-19-000086-index.htm
2019-10-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636050/000163605019000089/0001636050-19-000089-index.htm
2019-11-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1636050/000163605019000094/0001636050-19-000094-index.htm
2019-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636050/000163605019000095/0001636050-19-000095-index.htm
2019-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636050/000163605019000098/0001636050-19-000098-index.htm
2019-12-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636050/000163605019000103/0001636050-19-000103-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636050/000163605020000002/0001636050-20-000002-index.htm
2020-02-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1636050/000163605020000009/0001636050-20-000009-index.htm
2020-02-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636050/000163605020000010/0001636050-20-000010-index.htm
2020-04-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636050/000163605020000014/0001636050-20-000014-index.htm
2020-04-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636050/000163605020000019/0001636050-20-000019-index.htm
2020-06-1010-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1636050/000163605020000028/0001636050-20-000028-index.htm
2020-06-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636050/000163605020000029/0001636050-20-000029-index.htm
2020-08-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1636050/000163605020000035/0001636050-20-000035-index.htm
2020-08-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636050/000163605020000036/0001636050-20-000036-index.htm
2020-08-11S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1636050/000163605020000040/0001636050-20-000040-index.htm
2020-08-12DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1636050/000163605020000046/0001636050-20-000046-index.htm
2020-08-12DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1636050/000163605020000047/0001636050-20-000047-index.htm
2020-09-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636050/000163605020000049/0001636050-20-000049-index.htm
2020-10-02S-4Registration of securities, business combinationshttps://www.sec.gov/Archives/edgar/data/1636050/000163605020000052/0001636050-20-000052-index.htm
2020-10-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636050/000163605020000055/0001636050-20-000055-index.htm
2020-10-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636050/000163605020000057/0001636050-20-000057-index.htm
2020-10-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1636050/000163605020000061/0001636050-20-000061-index.htm
2020-06-15EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1636050/999999999520001423/9999999995-20-001423-index.htm
2019-03-06CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1636050/999999999719000761/9999999997-19-000761-index.htm

Sio Gene Therapies, Inc (AXGT) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Sio Gene Therapies, Inc (AXGT). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 3957%
Institutional Ownership: 2427%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-03-18Andrew Lo10% Share HolderBuy6,666,667.001.5010,000,000.50105,952,381.00https://www.sec.gov/Archives/edgar/data/1636050/000110465919016034/0001104659-19-016034-index.htm
2019-03-18GLOBAL INVESTORS LP VIKING10% Share HolderBuy6,666,667.001.5010,000,000.50105,952,381.00https://www.sec.gov/Archives/edgar/data/1636050/000090342319000151/0000903423-19-000151-index.htm
2019-03-18Holdings Ltd. Dexxon10% Share HolderBuy6,666,667.001.5010,000,000.50105,952,381.00https://www.sec.gov/Archives/edgar/data/1636050/000114420419014887/0001144204-19-014887-index.htm
2019-03-18Investments (UK) Ltd SVF10% Share HolderBuy6,666,667.001.5010,000,000.50105,952,381.00https://www.sec.gov/Archives/edgar/data/1636050/000120919119020327/0001209191-19-020327-index.htm
2019-03-18Patrick Machado10% Share HolderBuy6,666,667.001.5010,000,000.50105,952,381.00https://www.sec.gov/Archives/edgar/data/1636050/000110465919016043/0001104659-19-016043-index.htm
2019-03-18QVT Associates GP LLC10% Share HolderBuy6,666,667.001.5010,000,000.50105,952,381.00https://www.sec.gov/Archives/edgar/data/1636050/000089924319008356/0000899243-19-008356-index.htm
2019-03-18Sciences Ltd. Roivant10% Share HolderBuy6,666,667.001.5010,000,000.50105,952,381.00https://www.sec.gov/Archives/edgar/data/1636050/000110465919016010/0001104659-19-016010-index.htm
2019-03-18VIKING GLOBAL PERFORMANCE LLC10% Share HolderBuy6,666,667.001.5010,000,000.50105,952,381.00https://www.sec.gov/Archives/edgar/data/1636050/000090342319000152/0000903423-19-000152-index.htm
2020-03-16Atul PandeDirectorBuy10,000.001.7817,844.0013,370.00https://www.sec.gov/Archives/edgar/data/1636050/000120919120020125/0001209191-20-020125-index.htm
2020-06-12Gavin CorcoranChief R&D OfficerBuy16,002.0016,002.00https://www.sec.gov/Archives/edgar/data/1636050/000120919120036804/0001209191-20-036804-index.htm
2020-02-24Sciences Ltd. Roivant10% Share HolderBuy5,333,333.003.7519,999,998.7518,577,380.00https://www.sec.gov/Archives/edgar/data/1636050/000110465920026412/0001104659-20-026412-index.htm
2020-07-08Atul PandeDirectorBuy10,000.002.7327,290.0023,370.00https://www.sec.gov/Archives/edgar/data/1636050/000120919120042216/0001209191-20-042216-index.htm
2020-06-11David W. NassifPrincipal Financial OfficerBuy15,060.0024,210.00https://www.sec.gov/Archives/edgar/data/1636050/000120919120036808/0001209191-20-036808-index.htm
2020-06-11Pavan CheruvuPrincipal Executive OfficerBuy22,591.0030,091.00https://www.sec.gov/Archives/edgar/data/1636050/000120919120036807/0001209191-20-036807-index.htm
2019-06-14Atul PandeDirectorBuy3,370.005.2217,595.443,370.00https://www.sec.gov/Archives/edgar/data/1636050/000120919119037522/0001209191-19-037522-index.htm
2020-07-08Pavan CheruvuPrincipal Executive OfficerBuy37,500.002.74102,637.5057,836.00https://www.sec.gov/Archives/edgar/data/1636050/000120919120042215/0001209191-20-042215-index.htm
2019-06-14Pavan CheruvuChief Executive OfficerBuy7,500.005.2139,075.007,500.00https://www.sec.gov/Archives/edgar/data/1636050/000120919119037525/0001209191-19-037525-index.htm